Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 53, Issue 9, Pages 2516-2520Publisher
SPRINGER
DOI: 10.1007/s10620-007-0172-z
Keywords
inflammatory bowel diseases; antibodies; monoclonal; infliximab; octreotide; enterocolitis
Categories
Ask authors/readers for more resources
Indomethacin administration in animals increases permeability of the small intestine, leading to inflammation that mimics Crohn's disease. Nonsteroidal anti-inflammatory drugs increase the permeability of the intestinal epithelial barrier and should therefore be used with caution in patients with Crohn's disease. We analyzed the protective effects of octreotide and the tumor necrosis factor-alpha inhibitor infliximab in a rat model of indomethacin-induced enterocolitis. Male Wistar rats received 20 mg of infliximab or 10 mu g of octreotide 24 h prior to injection with indomethacin. Intestinal permeability was analyzed using Cr-51-ethylenediaminetetraacetic acid clearance. No microscopic or macroscopic alterations were observed in the rats receiving infliximab or octreotide, both of which increased permeability (P < 0.001 versus controls). Our macroscopic and microscopic findings might be related to the low specificity of infliximab and suggest that cytokines affect the intestinal epithelial barrier, as evidenced by the protective effect that infliximab had on the permeability parameters evaluated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available